<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0412222962
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Apeto
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        THIOTEPA
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous, Intravesical
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        powder for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        3
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        843.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MSN LABORATORIES PRIVATE LIMITED " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MSN LABORATORIES PRIVATE LIMITED 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2096]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Boston Oncology Arabia
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Boston Oncology Arabia
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01AC01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
            <div class="p-20 text-center font-20">
                <div class="p-10 bg-red"><i class="fa fa-times-circle"></i>&nbsp;&#x644;&#x645; &#x64A;&#x62A;&#x645; &#x625;&#x62F;&#x62E;&#x627;&#x644; &#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A;  &#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x644;&#x647;&#x630;&#x627; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621; &#x62D;&#x62A;&#x649; &#x627;&#x644;&#x622;&#x646;</div>
            </div>
    </div>
    <div id="A-div" class="box-data">
            <div class="p-20 text-center font-20">
                <span class="p-10 bg-red"><i class="fa fa-times-circle"></i>&nbsp;&#x644;&#x645; &#x64A;&#x62A;&#x645; &#x625;&#x62F;&#x62E;&#x627;&#x644; &#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A;  &#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x644;&#x647;&#x630;&#x627; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621; &#x62D;&#x62A;&#x649; &#x627;&#x644;&#x622;&#x646;</span>
            </div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Apeto
Thiotepa for Injection USP 15mg/vial 
Thiotepa for Injection USP 100mg/vial 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Thiotepa for Injection USP 15mg/vial 
Each vial contains 15 mg of Thiotepa USP. 

Thiotepa for Injection USP 100mg/vial 
Each vial contains 100 mg of Thiotepa USP. 

After reconstitution, each ml contains 10 mg of Thiotepa USP (10 mg/ml) 
For the full list of excipients, see section 6.1. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Before Reconstitution: White lyophilized powder. 
After reconstitution: Clear to hazy solution free from visible particulate matter. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Apeto&nbsp;is indicated, in combination with other chemotherapy medicinal products:&nbsp;</p><p dir="ltr">- with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or&nbsp; autologous haematopoietic progenitor cell transplantation (HPCT) in haematological&nbsp; diseases in adult and paediatric patients;&nbsp;</p><p dir="ltr">- when high-dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Apeto administration must be supervised by a physician experienced in conditioning treatment prior to hematopoietic progenitor cell transplantation.&nbsp;</p><p dir="ltr"><strong>Posology&nbsp;</strong></p><p dir="ltr">Apeto is administered at different doses, in combination with other chemotherapeutic medicinal products, in patients with hematological diseases or solid tumors prior to HPCT. Thiotepa posology is reported, in adult and pediatric patients, according to the type of HPCT&nbsp;<strong> </strong>(autologous or allogeneic) and disease.&nbsp;</p><p dir="ltr"><strong>Adults&nbsp;</strong></p><p dir="ltr">AUTOLOGOUS HPCT&nbsp;</p><p dir="ltr">Hematological diseases&nbsp;</p><p dir="ltr">The recommended dose in hematological diseases ranges from 125 mg/m2/day&nbsp; (3.38 mg/kg/day) to 300 mg/m2/day (8.10 mg/kg/day) as a single daily infusion, administered from 2 up to 4 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 900 mg/m2(24.32 mg/kg), during the time of the entire conditioning treatment.&nbsp;</p><p dir="ltr">LYMPHOMA&nbsp;</p><p dir="ltr">The recommended dose ranges from 125 mg/m2/day (3.38 mg/kg/day) to 300 mg/m2/day (8.10 mg/kg/day) as a single daily infusion, administered from 2 up to 4 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 900 mg/m2(24.32 mg/kg),&nbsp; during the time of the entire conditioning treatment.&nbsp;</p><p dir="ltr">CENTRAL NERVOUS SYSTEM (CNS) LYMPHOMA&nbsp;</p><p dir="ltr">The recommended dose is 185 mg/m2/day (5 mg/kg/day) as a single daily infusion,&nbsp; administered for 2 consecutive days before autologous HPCT, without exceeding the total maximum cumulative dose of 370 mg/m2(10 mg/kg), during the time of the entire conditioning treatment.&nbsp;</p><p dir="ltr">MULTIPLE MYELOMA&nbsp;</p><p dir="ltr">The recommended dose ranges from 150 mg/m2/day (4.05 mg/kg/day) to 250 mg/m2/day (6.76 mg/kg/day) as a single daily infusion, administered for 3 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 750 mg/m2(20.27 mg/kg),&nbsp; during the time of the entire conditioning treatment.&nbsp;</p><p dir="ltr">Solid tumors&nbsp;</p><p dir="ltr">The recommended dose in solid tumors ranges from 120 mg/m2/day (3.24 mg/kg/day) to 250 mg/m2/day (6.76 mg/kg/day) divided in one or two daily infusions, administered from 2 up to 5 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 800 mg/m2(21.62 mg/kg), during the time of the entire conditioning treatment.&nbsp;</p><p dir="ltr">BREAST CANCER&nbsp;</p><p dir="ltr">The recommended dose ranges from 120 mg/m2/day (3.24 mg/kg/day) to 250 mg/m2/day (6.76 mg/kg/day) as a single daily infusion, administered from 3 up to 5 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 800 mg/m2(21.62 mg/kg),&nbsp; during the time of the entire conditioning treatment.&nbsp;</p><p dir="ltr">CNS TUMOURS&nbsp;</p><p dir="ltr">The recommended dose ranges from 125 mg/m2/day (3.38 mg/kg/day) to 250 mg/m2/day (6.76 mg/kg/day) divided in one or two daily infusions, administered from 3 up to 4&nbsp; consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 750 mg/m2(20.27 mg/kg), during the time of the entire conditioning treatment.&nbsp;</p><p dir="ltr">OVARIAN CANCER&nbsp;</p><p dir="ltr">The recommended dose is 250 mg/m2/day (6.76 mg/kg/day) as a single daily infusion,&nbsp; administered in 2 consecutive days before autologous HPCT, without exceeding the total maximum cumulative dose of 500 mg/m2(13.51 mg/kg), during the time of the entire conditioning treatment.&nbsp;</p><p dir="ltr">GERM CELL TUMOURS&nbsp;</p><p dir="ltr">The recommended dose ranges from 150 mg/m2/day (4.05 mg/kg/day) to 250 mg/m2/day (6.76 mg/kg/day) as a single daily infusion, administered for 3 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 750 mg/m2(20.27 mg/kg),&nbsp; during the time of the entire conditioning treatment.&nbsp;</p><p dir="ltr">ALLOGENEIC HPCT&nbsp;</p><p dir="ltr">Hematological diseases&nbsp;</p><p dir="ltr">The recommended dose in hematological diseases ranges from 185 mg/m2/day (5 mg/kg/day)&nbsp; to 481 mg/m2/day (13 mg/kg/day) divided in one or two daily infusions, administered from 1 up to 3 consecutive days before allogeneic HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 555 mg/m2(15 mg/kg), during the time of the entire conditioning treatment.&nbsp;</p><p dir="ltr">LYMPHOMA&nbsp;</p><p dir="ltr">The recommended dose in lymphoma is 370 mg/m2/day (10 mg/kg/day) divided into two daily infusions before allogeneic HPCT, without exceeding the total maximum cumulative dose of&nbsp; 370 mg/m2(10 mg/kg), during the time of the entire conditioning treatment.&nbsp;</p><p dir="ltr">MULTIPLE MYELOMA&nbsp;</p><p dir="ltr">The recommended dose is 185 mg/m2/day (5 mg/kg/day) as a single daily infusion before allogeneic HPCT, without exceeding the total maximum cumulative dose of 185 mg/m2 (5 mg/kg), during the time of the entire conditioning treatment.&nbsp;</p><p dir="ltr">LEUKAEMIA&nbsp;</p><p dir="ltr">The recommended dose ranges from 185 mg/m2/day (5 mg/kg/day) to 481 mg/m2/day&nbsp; (13 mg/kg/day) divided in one or two daily infusions, administered from 1 up to 2 consecutive days before allogeneic HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 555 mg/m2 (15 mg/kg), during the time of the entire conditioning treatment.&nbsp;</p><p dir="ltr">THALASSEMIA&nbsp;</p><p dir="ltr">The recommended dose is 370 mg/m2/day (10 mg/kg/day) divided into two daily infusions,&nbsp; administered before allogeneic HPCT, without exceeding the total maximum cumulative dose of 370 mg/m2(10 mg/kg), during the time of the entire conditioning treatment.&nbsp;</p><p dir="ltr"><strong>Pediatric population&nbsp;</strong></p><p dir="ltr">AUTOLOGOUS HPCT&nbsp;</p><p dir="ltr">Solid tumors&nbsp;</p><p dir="ltr">The recommended dose in solid tumors ranges from 150 mg/m2/day (6 mg/kg/day) to&nbsp; 350 mg/m2/day (14 mg/kg/day) as a single daily infusion, administered from 2 up to&nbsp; 3 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 1050 mg/m2(42 mg/kg), during the time of the entire conditioning treatment.&nbsp;</p><p dir="ltr">CNS TUMOURS&nbsp;</p><p dir="ltr">The recommended dose ranges from 250 mg/m2/day (10 mg/kg/day) to 350 mg/m2/day&nbsp; (14 mg/kg/day) as a single daily infusion, administered for 3 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 1050 mg/m2(42 mg/kg),&nbsp; during the time of the entire conditioning treatment.&nbsp;</p><p dir="ltr">ALLOGENEIC HPCT&nbsp;</p><p dir="ltr">Hematological diseases&nbsp;</p><p dir="ltr">The recommended dose in hematological diseases ranges from 125 mg/m2/day (5 mg/kg/day)&nbsp; to 250 mg/m2/day (10 mg/kg/day) divided in one or two daily infusions, administered from 1 up to 3 consecutive days before allogeneic HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 375 mg/m2(15 mg/kg), during the time of the entire conditioning treatment.&nbsp;</p><p dir="ltr">LEUKAEMIA&nbsp;</p><p dir="ltr">The recommended dose is 250 mg/m2/day (10 mg/kg/day) divided into two daily infusions,&nbsp; administered before allogeneic HPCT, without exceeding the total maximum cumulative dose of 250 mg/m2(10 mg/kg), during the time of the entire conditioning treatment.&nbsp;</p><p dir="ltr">THALASSEMIA&nbsp;</p><p dir="ltr">The recommended dose ranges from 200 mg/m2/day (8 mg/kg/day) to 250 mg/m2/day&nbsp; (10 mg/kg/day) divided in two daily infusions, administered before allogeneic HPCT without exceeding the total maximum cumulative dose of 250 mg/m2(10 mg/kg), during the time of the entire conditioning treatment.&nbsp;</p><p dir="ltr">REFRACTORY CYTOPENIA&nbsp;</p><p dir="ltr">The recommended dose is 125 mg/m2/day (5 mg/kg/day) as a single daily infusion,&nbsp; administered for 3 consecutive days before allogeneic HPCT, without exceeding the total maximum cumulative dose of 375 mg/m2(15 mg/kg), during the time of the entire conditioning treatment.&nbsp;</p><p dir="ltr">GENETIC DISEASES&nbsp;</p><p dir="ltr">The recommended dose is 125 mg/m2/day (5 mg/kg/day) as a single daily infusion,&nbsp; administered for 2 consecutive days before allogeneic HPCT, without exceeding the total maximum cumulative dose of 250 mg/m2(10 mg/kg), during the time of the entire conditioning treatment.&nbsp;</p><p dir="ltr">SICKLE CELL ANAEMIA&nbsp;</p><p dir="ltr">The recommended dose is 250 mg/m2/day (10 mg/kg/day) divided into two daily infusions,&nbsp; administered before allogeneic HPCT, without exceeding the total maximum cumulative dose&nbsp;of 250 mg/m2(10 mg/kg), during the time of the entire conditioning treatment.&nbsp;</p><p dir="ltr"><strong>Special populations&nbsp;</strong></p><p dir="ltr">Renal impairment&nbsp;</p><p dir="ltr">Studies in renally impaired patients have not been conducted. As thiotepa and its metabolites are poorly excreted in the urine, dose modification is not recommended in patients with mild or moderate renal insufficiency. However, caution is recommended (see sections 4.4 and 5.2).&nbsp;</p><p dir="ltr">Hepatic impairment&nbsp;</p><p dir="ltr">Thiotepa has not been studied in patients with hepatic impairment. Since thiotepa is mainly metabolized through the liver, caution needs to be exercised when thiotepa is used in patients with pre-existing impairment of liver function, especially in those with severe hepatic impairment. Dose modification is not recommended for transient alterations of hepatic parameters (see section 4.4).&nbsp;</p><p dir="ltr">Elderly&nbsp;</p><p dir="ltr">The administration of thiotepa has not been specifically investigated in elderly patients.&nbsp; However, in clinical studies, a proportion of patients over the age of 65 received the same cumulative dose as the other patients. No dose adjustment was deemed necessary.&nbsp;</p><p dir="ltr"><strong>Method of administration&nbsp;</strong></p><p dir="ltr">Apeto must be administered by a qualified healthcare professional as a 2-4 hours intravenous infusion via a central venous catheter.&nbsp;</p><p dir="ltr"><strong>Thiotepa for Injection USP 15mg/vial&nbsp;&nbsp;</strong></p><p dir="ltr">Each Apeto vial must be reconstituted with 1.5 ml of sterile water for injection USP. The total volume of reconstituted vials to be administered should be further diluted in 500 ml of sodium chloride 9 mg/ml (0.9%) solution for injection prior to administration (1,000 ml if the dose is higher than 500 mg). In children, if the dose is lower than 250 mg, an appropriate volume of sodium chloride 9 mg/ml (0.9%) solution for injection may be used in order to obtain a final Apeto concentration between 0.5 and 1 mg/ml. For instructions on reconstitution and further dilution prior to administration, see section 6.6.&nbsp;</p><p dir="ltr"><strong>Thiotepa for Injection USP 100mg/vial&nbsp;</strong></p><p dir="ltr">Each Apeto vial must be reconstituted with 10 ml of sterile water for injection USP. The total volume of reconstituted vials to be administered should be further diluted in 500 ml of sodium chloride 9 mg/ml (0.9%) solution for injection prior to administration (1,000 ml if the dose is higher than 500 mg). In children, if the dose is lower than 250 mg, an appropriate volume of sodium chloride 9 mg/ml (0.9%) solution for injection may be used in order to obtain a final&nbsp; Apeto concentration between 0.5 and 1 mg/ml. For instructions on reconstitution and further dilution prior to administration, see section 6.6.&nbsp;</p><p dir="ltr"><strong>Precautions to be taken before handling or administering the medicinal product&nbsp;</strong></p><p dir="ltr">Topical reactions associated with accidental exposure to thiotepa may occur. Therefore, the use of gloves is recommended in preparing the solution for infusion. If the thiotepa solution accidentally contacts the skin, the skin must be immediately thoroughly washed with soap and water. If thiotepa accidentally contacts mucous membranes, they must be flushed thoroughly with water (see section 6.6).&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance. 
Pregnancy and lactation (see section 4.6). 
Concomitant use with yellow fever vaccine and with live virus and bacterial vaccines (see section 4.5). 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The consequence of treatment with thiotepa at the recommended dose and schedule is profound myelosuppression, occurring in all patients. Severe granulocytopenia, thrombocytopenia, anemia, or any combination thereof may develop. Frequent complete blood counts, including differential white blood cell counts, and platelet counts need to be performed during the treatment and until recovery is achieved. Platelet and red blood cell support, as well as the use&nbsp;of growth factors such as Granulocyte-colony stimulating factor (G-CSF), should be employed as medically indicated. Daily white blood cell counts and platelet counts are recommended during therapy with thiotepa and after transplant for at least 30 days.&nbsp;</p><p dir="ltr">Prophylactic or empiric use of anti-infectives (bacterial, fungal, viral) should be considered for the prevention and management of infections during the neutropenic period.&nbsp;</p><p dir="ltr">Thiotepa has not been studied in patients with hepatic impairment. Since thiotepa is mainly metabolized through the liver, caution needs to be observed when thiotepa is used in patients with pre-existing impairment of liver function, especially in those with severe hepatic impairment. When treating such patients it is recommended that serum transaminase, alkaline phosphatase, and bilirubin are monitored regularly following transplant, for early detection of hepatotoxicity.&nbsp;</p><p dir="ltr">Patients who have received prior radiation therapy, greater than or equal to three cycles of chemotherapy, or prior progenitor cell transplant may be at an increased risk of hepatic veno occlusive disease (see section 4.8).&nbsp;</p><p dir="ltr">Caution must be used in patients with a history of cardiac diseases, and cardiac function must be monitored regularly in patients receiving thiotepa.&nbsp;</p><p dir="ltr">Caution must be used in patients with a history of renal diseases and periodic monitoring of renal function should be considered during therapy with thiotepa.&nbsp;</p><p dir="ltr">Thiotepa might induce pulmonary toxicity that may be additive to the effects produced by other cytotoxic agents (busulfan, fludarabine, and cyclophosphamide) (see section 4.8).&nbsp;</p><p dir="ltr">Previous brain irradiation or craniospinal irradiation may contribute to severe toxic reactions&nbsp; (e.g. encephalopathy).&nbsp;</p><p dir="ltr">The increased risk of a secondary malignancy with thiotepa, a known carcinogen in humans,&nbsp; must be explained to the patient.&nbsp;</p><p dir="ltr">Concomitant use with live attenuated vaccines (except yellow fever vaccines), phenytoin, and fosphenytoin is not recommended (see section 4.5).&nbsp;</p><p dir="ltr">Thiotepa must not be concurrently administered with cyclophosphamide when both medicinal products are present in the same conditioning treatment. Thiotepa must be delivered after the completion of any cyclophosphamide infusion (see section 4.5).&nbsp;</p><p dir="ltr">During the concomitant use of thiotepa and inhibitors of CYP2B6 or CYP3A4, patients should be carefully monitored clinically (see section 4.5).&nbsp;</p><p dir="ltr">As with most alkylating agents, thiotepa might impair male or female fertility. Male patients should seek for sperm cryopreservation before therapy is started and should not father a child while treated and during the year after cessation of treatment (see section 4.6).&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Specific interactions with thiotepa&nbsp;</strong></p><p dir="ltr">Live virus and bacterial vaccines must not be administered to a patient receiving an immunosuppressive chemotherapeutic agent and at least three months must elapse between discontinuation of therapy and vaccination.&nbsp;</p><p dir="ltr">Thiotepa appears to be metabolized via CYP2B6 and CYP3A4. Co-administration with inhibitors of CYP2B6 (for example clopidogrel and ticlopidine) or CYP3A4 (for example azole antifungals, macrolides like erythromycin, clarithromycin, telithromycin, and protease inhibitors) may increase the plasma concentrations of thiotepa and potentially decrease the concentrations of the active metabolite triethylenephosphoramide (TEPA). Co-administration of inducers of cytochrome P450 (such as rifampicin, carbamazepine, and phenobarbital) may increase the metabolism of thiotepa leading to increased plasma concentrations of the active metabolite. Therefore, during the concomitant use of thiotepa and these medicinal products,&nbsp; patients should be carefully monitored clinically.&nbsp;</p><p dir="ltr">Thiotepa is a weak inhibitor of CYP2B6, and may thereby potentially increase plasma concentrations of substances metabolized via CYP2B6, such as ifosfamide, tamoxifen,&nbsp; bupropion, efavirenz, and cyclophosphamide. CYP2B6 catalyzes the metabolic conversion of cyclophosphamide to its active form 4-hydroxy cyclophosphamide (4-OHCP) and co-administration&nbsp;of thiotepa may therefore lead to decreased concentrations of the active 4- OHCP. Therefore, clinical monitoring should be exercised during the concomitant use of thiotepa and these medicinal products<strong>.</strong></p><p dir="ltr"><strong>Contraindications of concomitant use&nbsp;</strong></p><p dir="ltr">Yellow fever vaccine: risk of fatal generalized vaccine-induced disease.&nbsp;</p><p dir="ltr">More generally, live virus and bacterial vaccines must not be administered to a patient receiving an immunosuppressive chemotherapeutic agent and at least three months must elapse between discontinuation of therapy and vaccination.</p><p dir="ltr"><strong>Concomitant use not recommended&nbsp;</strong></p><p dir="ltr">Live attenuated vaccines (except yellow fever): risk of a systemic, possibly fatal disease. This risk is increased in subjects who are already immunosuppressed by their underlying disease.&nbsp;</p><p dir="ltr">An inactivated virus vaccine should be used instead, whenever possible (poliomyelitis).&nbsp;</p><p dir="ltr">Phenytoin: risk of exacerbation of convulsions resulting from the decrease of phenytoin digestive absorption by cytotoxic medicinal product or risk of toxicity enhancement and loss of efficacy of the cytotoxic medicinal product due to increased hepatic metabolism by phenytoin.</p><p dir="ltr"><strong>Concomitant use to take into consideration&nbsp;</strong></p><p dir="ltr">Cyclosporine, tacrolimus: excessive immunosuppression with risk of lymphoproliferation.&nbsp;</p><p dir="ltr">Alkylating chemotherapeutic agents, including thiotepa, inhibit plasma pseudocholinesterase by&nbsp; 35% to 70%. The action of succinyl-choline can be prolonged by 5 to 15 minutes.&nbsp;</p><p dir="ltr">Thiotepa must not be concurrently administered with cyclophosphamide when both medicinal products are present in the same conditioning treatment. Thiotepa must be delivered after the completion of any cyclophosphamide infusion.&nbsp;</p><p dir="ltr">The concomitant use of thiotepa and other myelosuppressive or myelotoxic agents (i.e. cyclophosphamide, melphalan, busulfan, fludarabine, treosulfan) may potentiate the risk of haematologic adverse reactions due to overlapping toxicity profiles of these medicinal products.</p><p dir="ltr"><strong>Interaction common to all cytotoxics&nbsp;</strong></p><p dir="ltr">Due to the increase of thrombotic risk in case of malignancy, the use of anticoagulative treatment is frequent. The high intra-individual variability of the coagulation state during malignancy, and the potential interaction between oral anticoagulants and anticancer chemotherapy require, if it is decided to treat the patient with oral anticoagulants, to increase the frequency of the INR (International Normalised Ratio) monitoring.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Women of childbearing potential</strong></p><p dir="ltr">Women of childbearing potential have to use effective contraception during treatment and a&nbsp; pregnancy test should be performed before treatment is started.&nbsp;</p><p dir="ltr"><strong>Pregnancy</strong>&nbsp;</p><p dir="ltr">There are no data on the use of thiotepa during pregnancy. In preclinical studies, thiotepa, like most alkylating agents, has been shown to cause embryofoetal lethality and teratogenicity (see section 5.3). Therefore, thiotepa is contraindicated during pregnancy.&nbsp;</p><p dir="ltr"><strong>Breast-feeding&nbsp;</strong></p><p dir="ltr">It is unknown whether thiotepa is excreted in human milk. Due to its pharmacological properties and its potential toxicity for breastfed newborns/infants, breastfeeding is contraindicated during treatment with thiotepa.</p><p dir="ltr"><strong>Fertility&nbsp;</strong></p><p dir="ltr">As with most alkylating agents, thiotepa might impair male and female fertility. Male patients should seek for sperm cryopreservation before therapy is started and should not father a child while treated and during the year after cessation of treatment (see section 5.3).&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Thiotepa may have a major influence on the ability to drive and use machines. It is likely that certain adverse reactions of thiotepa like dizziness, headache, and blurred vision could affect these functions.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Summary of the safety profile&nbsp;</strong></p><p dir="ltr">The safety of thiotepa has been examined through a review of adverse events reported in published data from clinical trials. In these studies, a total of 6,588 adult patients and 902&nbsp; paediatric patients received thiotepa for conditioning treatment prior to haematopoietic progenitor cell transplantation.&nbsp;</p><p dir="ltr">Serious toxicities involving the haematologic, hepatic and respiratory systems were considered as expected consequences of the conditioning regimen and transplant process. These include infection and Graft-versus-host disease (GvHD) which, although not directly related, were the major causes of morbidity and mortality, especially in allogeneic HPCT.&nbsp;</p><p dir="ltr">The most frequent adverse reactions reported in the different conditioning treatments including thiotepa are infections, cytopenia, acute GvHD and chronic GvHD, gastrointestinal disorders, haemorrhagic cystitis, and mucosal inflammation.&nbsp;</p><p dir="ltr"><strong>Leukoencephalopathy&nbsp;</strong></p><p dir="ltr">Cases of leukoencephalopathy have been observed following treatment with thiotepa in adult and paediatric patients with multiple previous chemotherapies, including methotrexate and radiotherapy. Some cases had a fatal outcomes.&nbsp;</p><p dir="ltr">Tabulated list of adverse reactions&nbsp;</p><p dir="ltr"><strong>Adults</strong>&nbsp;</p><p dir="ltr">The adverse reactions considered at least possibly related to conditioning treatment including thiotepa, reported in adult patients as more than an isolated case, are listed below by system organ class and by frequency. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. Frequencies are defined as: very common (&ge;1/10),&nbsp; common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000) very rare (&lt;1/10,000), not known (cannot be estimated from the available data).&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:98%"><tbody><tr><td style="vertical-align:top"><p><strong>System</strong></p><p><strong>organ</strong></p><p><strong>class</strong></p></td><td style="vertical-align:top"><p><strong>Very common</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Not known</strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Infection</p><p>susceptibility</p><p>increased</p><p>Sepsis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Toxic shock</p><p>syndrome</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Neoplasms</p><p>benign, malignant and unspecified</p><p>(incl cysts and polyps)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Treatment related</p><p>second malignancy</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood and</p><p>lymphatic system</p><p>disorders</p></td><td style="vertical-align:top"><p>Leukopenia</p><p>Thrombocytopenia</p><p>Febrile neutropenia</p><p>Anaemia</p><p>Pancytopenia</p><p>Granulocytopenia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immune system</p><p>disorders</p></td><td style="vertical-align:top"><p>Acute graft versus</p><p>host disease</p><p>Chronic graft versus host disease</p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Endocrine</p><p>disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypopituitarism</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and</p><p>nutrition disorders</p></td><td style="vertical-align:top"><p>Anorexia</p><p>Decreased appetite</p><p>Hyperglycaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric</p><p>disorders</p></td><td style="vertical-align:top"><p>Confusional state</p><p>Mental status</p><p>changes</p></td><td style="vertical-align:top"><p>Anxiety</p></td><td style="vertical-align:top"><p>Delirium</p><p>Nervousness</p><p>Hallucination</p><p>Agitation</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system</p><p>disorders</p></td><td style="vertical-align:top"><p>Dizziness</p><p>Headache</p><p>Vision blurred</p><p>Encephalopathy</p><p>Convulsion</p><p>Paraesthesia</p></td><td style="vertical-align:top"><p>Intracranial aneurysm</p><p>Extrapyramidal</p><p>disorder</p><p>Cognitive disorder</p><p>Cerebral</p><p>haemorrhage</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Leukoencephalopathy</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Conjunctivitis</p></td><td style="vertical-align:top"><p>Cataract</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth</p><p>disorders</p></td><td style="vertical-align:top"><p>Hearing impaired</p><p>Ototoxicity</p><p>Tinnitus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Arrhythmia</p></td><td style="vertical-align:top"><p>Tachycardia</p><p>Cardiac failure</p></td><td style="vertical-align:top"><p>Cardiomyopathy</p><p>Myocarditis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Lymphoedema</p><p>Hypertension</p></td><td style="vertical-align:top"><p>Haemorrhage</p><p>Embolism</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory,</p><p>thoracic and</p><p>mediastinal</p><p>disorders</p></td><td style="vertical-align:top"><p>Idiopathic pneumonia syndrome</p><p>Epistaxis</p></td><td style="vertical-align:top"><p>Pulmonary oedema</p><p>Cough</p><p>Pneumonitis</p></td><td style="vertical-align:top"><p>Hypoxia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal</p><p>disorders</p></td><td style="vertical-align:top"><p>Nausea</p><p>Stomatitis</p><p>Oesophagitis</p><p>Vomiting</p><p>Diarrhoea</p><p>Dyspepsia</p><p>Abdominal pain</p><p>Enteritis</p></td><td style="vertical-align:top"><p>Constipation</p><p>Gastrointestinal</p><p>perforation</p><p>Ileus</p></td><td style="vertical-align:top"><p>Gastrointestinal ulcer</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliay</p><p>disorders</p></td><td style="vertical-align:top"><p>Venoocclusive liver</p><p>disease</p><p>Hepatomegaly</p><p>Jaundice</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and</p><p>subcutaneous</p><p>tissue disorders</p></td><td style="vertical-align:top"><p>Rash</p><p>Pruritus</p><p>Alopecia</p></td><td style="vertical-align:top"><p>Erythema</p></td><td style="vertical-align:top"><p>Pigmentation</p><p>disorder</p><p>Erythrodermic</p><p>psoriasis</p></td><td style="vertical-align:top"><p>Severe toxic</p><p>skin reactions</p><p>including cases</p><p>of Stevens-</p><p>Johnson</p><p>syndrome and</p><p>toxic epidermal</p><p>necrolysis</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Back pain</p><p>Myalgia</p><p>Arthralgia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary</p><p>disorders</p></td><td style="vertical-align:top"><p>Cystitis</p><p>haemorrhagic</p></td><td style="vertical-align:top"><p>Dysuria</p><p>Oliguria</p><p>Renal failure</p><p>Cystitis</p><p>Haematuria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive</p><p>system and breast</p><p>disorders</p></td><td style="vertical-align:top"><p>Azoospermia</p><p>Amenorrhoea</p><p>Vaginal haemorrhage</p></td><td style="vertical-align:top"><p>Menopausal symptoms Infertility female</p><p>Infertility male</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and</p><p>Administratin site conditions</p></td><td style="vertical-align:top"><p>Pyrexia</p><p>Asthenia</p><p>Chills</p><p>Generalised oedema</p><p>Injection site</p><p>inflammation</p><p>Injection site pain</p><p>Mucosal</p><p>inflammation</p></td><td style="vertical-align:top"><p>Multi-organ failure</p><p>Pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Investigation</p></td><td style="vertical-align:top"><p>Weight increased</p><p>Blood bilirubin</p><p>increased</p><p>Transaminases</p><p>increased</p><p>Blood amylase</p><p>increased</p></td><td style="vertical-align:top"><p>Blood creatinine</p><p>increased</p><p>Blood urea increased</p><p>&nbsp;</p><p>Gamma-</p><p>glutamyltransferase</p><p>&nbsp;</p><p>increased</p><p>Blood alkaline</p><p>phosphatase</p><p>increased</p><p>Aspartate</p><p>aminotransferase</p><p>increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><strong>Paediatric population</strong><br />The adverse reactions considered at least possibly related to conditioning treatment including thiotepa, reported in paediatric patients as more than an isolated case, are listed below by system organ class and by frequency. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. Frequencies are defined as very common (&ge;1/10),<br />common ((&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000) very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><table border="1" cellspacing="0" cellpadding="0" style="width:87%"><tbody><tr><td style="vertical-align:top"><p><strong>System</strong></p><p><strong>organ</strong></p><p><strong>class</strong></p></td><td style="vertical-align:top"><p><strong>Very common</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and</p><p>infestations</p></td><td style="vertical-align:top"><p>Infection susceptibility</p><p>increased</p><p>Sepsis</p></td><td style="vertical-align:top"><p>Thrombocytopenic</p><p>purpura</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Neoplasms benign,</p><p>malignant and</p><p>unspecified (incl cysts</p><p>and polyps)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Treatment related second</p><p>malignancy</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic</p><p>system</p><p>disorders</p></td><td style="vertical-align:top"><p>Thrombocytopenia</p><p>Febrile neutropenia</p><p>Anaemia</p><p>Pancytopenia</p><p>Granulocytopenia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immune system</p><p>disorders</p></td><td style="vertical-align:top"><p>Acute graft versus host disease Chronic graft versus host disease</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top"><p>Hypopituitarism</p><p>Hypogonadism</p><p>Hypothyroidism</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and</p><p>nutrition disorders</p></td><td style="vertical-align:top"><p>Anorexia</p><p>Hyperglycaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Mental status changes</p></td><td style="vertical-align:top"><p>Mental disorder due to a</p><p>general medical</p><p>condition</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system</p><p>disorders</p></td><td style="vertical-align:top"><p>Headache</p><p>Encephalopathy</p><p>Convulsion</p><p>Cerebral hemorrhage</p><p>Memory impairment</p><p>Paresis</p></td><td style="vertical-align:top"><p>Ataxia</p></td><td style="vertical-align:top"><p>Leukoencephalopathy</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth</p><p>disorders</p></td><td style="vertical-align:top"><p>Hearing impaired</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Cardiac arrest</p></td><td style="vertical-align:top"><p>Cardiovascular</p><p>insufficiency</p><p>Cardiac failure</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Haemorrhage</p></td><td style="vertical-align:top"><p>Hypertension</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic</p><p>and mediastinal</p><p>disorders</p></td><td style="vertical-align:top"><p>Pneumonitis</p></td><td style="vertical-align:top"><p>Idiopathic pneumonia</p><p>syndrome</p><p>Pulmonary haemorrage</p><p>Pulmonary oedema</p><p>Epistaxis</p><p>Hypoxia</p><p>Respiratory arrest</p></td><td style="vertical-align:top"><p>Pulmonary arterial</p><p>hypertension</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal</p><p>disorders</p></td><td style="vertical-align:top"><p>Nausea</p><p>Stomatitis</p><p>Vomiting</p><p>Diarrhoea</p><p>Abdominal pain</p></td><td style="vertical-align:top"><p>Enteritis</p><p>Intestinal obstruction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary</p><p>disorders</p></td><td style="vertical-align:top"><p>Venoocclusive liver</p><p>disease</p></td><td style="vertical-align:top"><p>Liver failure</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous</p><p>tissue disorders</p></td><td style="vertical-align:top"><p>Rash</p><p>Erythema</p><p>Desquamation</p><p>Pigmentation disorder</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Severe toxic skin</p><p>reactions including</p><p>cases of Stevens-</p><p>Johnson syndrome</p><p>and toxic epidermal</p><p>necrolysis</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and</p><p>connective tissue</p><p>disorders</p></td><td style="vertical-align:top"><p>Growth retardation</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary</p><p>disorders</p></td><td style="vertical-align:top"><p>Bladder disorders</p></td><td style="vertical-align:top"><p>Renal failure</p><p>Cystitis</p><p>haemorrhagic</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and</p><p>administration site</p><p>conditions</p></td><td style="vertical-align:top"><p>Pyrexia</p><p>Mucosal inflammation</p><p>Pain</p><p>Multi-organ failure</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Investigation</p></td><td style="vertical-align:top"><p>Blood bilirubin increased</p><p>Transaminases increased</p><p>Blood creatinine</p><p>increased</p><p>Aspartate</p><p>aminotransferase</p><p>increased</p><p>Alanine aminotransferase</p><p>increased</p></td><td style="vertical-align:top"><p>Blood urea increased</p><p>Blood electrolytes</p><p>abnormal</p><p>Prothrombin time ratio</p><p>increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><strong>To report any side effect(s):</strong><br />Reporting suspected adverse reactions after authorisation of the medicinal product is important.<br />It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare<br />professionals are asked to report any suspected adverse reactions to the competent authority in<br />Saudi Arabia as per details below:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><u>Saudi Arabia</u></strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance Centre (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - SFDA Call Centre: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - Website: https://ade.sfda.gov.sa/</p><p><strong><u>&nbsp;</u></strong></p></td></tr></tbody></table><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><u>Other GCC States</u></strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no experience with overdoses of thiotepa. The most important adverse reactions<br />expected in case of overdose are myeloablation and pancytopenia.<br />There is no known antidote for thiotepa.<br />The hematological status needs to be closely monitored and vigorous supportive measures<br />instituted as medically indicated.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antineoplastic agents, Alkylating Agents, ATC code: L01AC01<br /><u>Mechanism of action</u><br />Thiotepa is a polyfunctional cytotoxic agent related chemically and pharmacologically to the<br />nitrogen mustard. The radiomimetic action of thiotepa is believed to occur through the release<br />of ethylene imine radicals that, as in the case of irradiation therapy, disrupt the bonds of DNA,<br />e.g. by alkylation of guanine at the N-7, breaking the linkage between the purine base and the<br />sugar and liberating alkylated guanine.</p><p><u>Clinical Safety and efficacy</u><br />The conditioning treatment must provide cytoreduction and ideally disease eradication.<br />Thiotepa has marrow ablation as its dose-limiting toxicity, allowing significant dose escalation<br />with the infusion of autologous HPCT. In allogeneic HPCT, the conditioning treatment must be<br />sufficiently immunosuppressive and myeloablative to overcome host rejection of the graft. Due<br />to its highly myeloablative characteristics, thiotepa enhances recipient immunosuppression and</p><p>myeloablation, thus strengthening engraftment; this compensates for the loss of the GvHD-<br />related GvL effects. As an alkylating agent, thiotepa produces the most profound inhibition of</p><p>tumor cell growth in vitro with the smallest increase in medicinal product concentration. Due<br />to its lack of extramedullary toxicity despite dose escalation beyond myelotoxic doses, thiotepa<br />has been used for decades in combination with other chemotherapy medicinal products prior to<br />autologous and allogeneic HPCT.<br />The results of published clinical studies supporting the efficacy of thiotepa are summarised:<br />Autologous HPCT.</p><p><u>Hematological diseases</u><br />Engraftment: Conditioning treatments including thiotepa have proved to be myeloablative.<br />Disease-Free Survival (DFS): An estimated 43% at five years has been reported, confirming<br />that conditioning treatments containing thiotepa following autologous HPCT are effective<br />therapeutic strategies for treating patients with hematological diseases.<br />Relapse: In all conditioning treatments containing thiotepa, relapse rates at more than 1 year<br />have been reported as being 60% or lower, which was considered by the physicians as the<br />threshold to prove efficacy. In some of the conditioning treatments evaluated, relapse rates<br />lower than 60% have also been reported at 5 years.<br />Overall Survival (OS): OS ranged from 29% to 87% with a follow-up ranging from 22 to 63<br />months.</p><p>Regimen Related Mortality (RRM) and Transplant Related Mortality (TRM): RRM values<br />ranging from 2.5% to 29% have been reported. TRM values ranged from 0% to 21% at 1 year,<br />confirming the safety of the conditioning treatment including thiotepa for autologous HPCT in<br />adult patients with hematological diseases.<br /><u>Solid tumors</u><br />Engraftment: Conditioning treatments including thiotepa have proved to be myeloablative.<br />Disease-Free Survival (DFS): Percentages reported with follow-up periods of more than 1 year<br />confirm that conditioning treatments containing thiotepa following autologous HPCT are<br />effective choices for treating patients with solid tumors.<br />Relapse: In all conditioning treatments containing thiotepa, relapse rates at more than 1 year<br />have been reported as being lower than 60%, which was considered by the physicians as the<br />threshold to prove efficacy. In some cases, relapse rates of 35% and of 45% have been reported<br />at 5 years and 6 years respectively.<br />Overall Survival: OS ranged from 30% to 87% with a follow-up ranging from 11.7 up to 87<br />months.<br />Regimen Related Mortality (RRM) and Transplant Related Mortality (TRM): RRM values<br />ranging from 0% to 2% have been reported. TRM values ranged from 0% to 7.4% confirming<br />the safety of the conditioning treatment including thiotepa for autologous HPCT in adult<br />patients with solid tumors.</p><p>Allogeneic HPCT<br /><u>Hematological diseases</u><br />Engraftment: Engraftment has been achieved (92%-100%) in all reported conditioning<br />treatments and it was considered to occur at the expected time. Therefore it can be concluded<br />that conditioning treatments including thiotepa are myeloablative.<br />GvHD (graft versus host disease): all conditioning treatments evaluated assured a low<br />incidence of acute GvHD grade III-IV (from 4% to 24%).<br />Disease-Free Survival (DFS): Percentages reported with follow-up periods of more than 1 year<br />and up to 5 years confirm that conditioning treatments containing thiotepa following allogeneic<br />HPCT are an effective choice for treating patients with hematological diseases.<br />Relapse: In all conditioning treatments containing thiotepa, relapse rates at more than 1 year<br />have been reported as being lower than 40% (which was considered by the physicians as the<br />threshold to prove efficacy). In some cases, relapse rates lower than 40% have also been<br />reported at 5 years and 10 years.<br />Overall Survival: OS ranged from 31% to 81% with a follow-up ranging from 7.3 up to 120<br />months.<br />Regimen Related Mortality (RRM) and Transplant Related Mortality (TRM): low values have<br />been reported, confirming the safety of the conditioning treatments including thiotepa for<br />allogeneic HPCT in adult patients with hematological diseases.</p><p><em>Pediatric population</em><br />Autologous HPCT</p><p><u>Solid tumors</u><br />Engraftment: It has been achieved with all reported conditioning regimens including thiotepa.<br />Disease-Free Survival (DFS): With a follow-up of 36 to 57 months, DFS ranged from 46% to<br />70% in the reported studies. Considering that all patients were treated for high-risk solid<br />tumors, DFS results confirm that conditioning treatments containing thiotepa following<br />autologous HPCT are effective therapeutic strategies for treating pediatric patients with solid<br />tumors.<br />Relapse: In all the reported conditioning regimens containing thiotepa, relapse rates at 12 to 57<br />months ranged from 33% to 57%. Considering that all patients suffer of recurrence or poor<br />prognosis solid tumors, these rates support the efficacy of conditioning regimens based on<br />thiotepa.<br />Overall Survival (OS): OS ranged from 17% to 84% with a follow-up ranging from 12.3 up to<br />99.6 months.</p><p>Regimen Related Mortality (RRM) and Transplant Related Mortality (TRM): RRM values<br />ranging from 0% to 26.7% have been reported. TRM values ranged from 0% to 18%<br />confirming the safety of the conditioning treatments including thiotepa for autologous HPCT in<br />pediatric patients with solid tumors.</p><p>Allogeneic HPCT<br /><u>Hematological diseases</u><br />Engraftment: It has been achieved with all evaluated conditioning regimens including thiotepa<br />with a success rate of 96% - 100%. The hematological recovery is in the expected time.<br />Disease-Free Survival (DFS): Percentages of 40% - 75% with follow-up of more than 1 year<br />have been reported. DFS results confirm that conditioning treatment containing thiotepa<br />following allogeneic HPCT is an effective therapeutic strategy for treating pediatric patients<br />with hematological diseases.<br />Relapse: In all the reported conditioning regimens containing thiotepa, the relapse rate was in<br />the range of 15% - 44%. These data support the efficacy of conditioning regimens based on<br />thiotepa in all hematological diseases.<br />Overall Survival (OS): OS ranged from 50% to 100% with a follow-up ranging from 9.4 up to<br />121 months.<br />Regimen Related Mortality (RRM) and Transplant Related Mortality (TRM): RRM values<br />ranging from 0% to 2.5% have been reported. TRM values ranged from 0% to 30% confirming<br />the safety of the conditioning treatment including thiotepa for allogeneic HPCT in pediatric<br />patients with hematological diseases.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u><br />Thiotepa is unreliably absorbed from the gastrointestinal tract: acid instability prevents thiotepa<br />from being administered orally.<br /><u>Distribution</u><br />Thiotepa is a highly lipophilic compound. After intravenous administration, plasma concentrations of the active substance fit a two-compartment model with a rapid distribution phase. The volume of distribution of thiotepa is large and it has been reported as ranging from<br />40.8 l/m2 to 75 l/m2, indicating distribution to total body water. The apparent volume of<br />distribution of thiotepa appears independent of the administered dose. The fraction unbound to<br />proteins in plasma is 70-90%; insignificant binding of thiotepa to gamma globulin and minimal<br />albumin binding (10-30%) has been reported.<br />After intravenous administration, CSF medicinal product exposure is nearly equivalent to that<br />achieved in plasma; the mean ratio of AUC in CSF to plasma for thiotepa is 0.93. CSF and<br />plasma concentrations of triethylenephosphoramide (TEPA), the first reported active metabolite<br />of thiotepa, exceed the concentrations of the parent compound.<br /><u>Biotransformation</u><br />Thiotepa undergoes rapid and extensive hepatic metabolism and metabolites could be detected<br />in urine within 1 hour after infusion. The metabolites are active alkylating agents but the role<br />they play in the antitumor activity of thiotepa remains to be elucidated. Thiotepa undergoes<br />oxidative desulphuration via the cytochrome P450 CYP2B and CYP3A isoenzyme families to<br />the major and active metabolite TEPA (triethylenephosphoramide). The total excreted amount<br />of thiotepa and its identified metabolites accounts for 54-100% of the total alkylating activity,<br />indicating the presence of other alkylating metabolites. During the conversion of GSH conjugates to N-acetylcysteine conjugates, GSH, cysteinyl glycine, and cysteine conjugates are formed.<br />These metabolites are not found in urine, and, if formed, are probably excreted in bile or as<br />intermediate metabolites rapidly converted into thiotepa-mercapturic.<br /><u>Elimination</u><br />The total clearance of thiotepa ranged from 11.4 to 23.2 l/h/m2. The elimination half-life varied from 1.5 to 4.1 hours. The identified metabolites TEPA, monochlorotepa, and thiotepa-<br />mercapturic are all excreted in the urine. Urinary excretion of thiotepa and TEPA is nearly-complete&nbsp;after 6 and 8 hours respectively. The mean urinary recovery of thiotepa and its&nbsp;metabolites is 0.5% for the unchanged medicinal product and monochlorotepa, and 11% for<br />TEPA and thiotepa-mercapturic.</p><p><u>Linearity/non-linearity</u><br />There is no clear evidence of saturation of metabolic clearance mechanisms at high doses of<br />thiotepa.<br /><u>Special populations</u><br /><em>Pediatric population</em><br />The pharmacokinetics of high-dose thiotepa in children between 2 and 12 years of age do not<br />appear to vary from those reported in children receiving 75 mg/m2 or adults receiving similar doses.<br /><em>Renal impairment</em><br />The effects of renal impairment on thiotepa elimination have not been assessed.<br /><em>Hepatic impairment</em><br />The effects of hepatic impairment on thiotepa metabolism and elimination have not been<br />assessed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No conventional acute and repeat dose toxicity studies were performed.<br />Thiotepa was shown to be genotoxic in vitro and in vivo, and carcinogenic in mice and rats.<br />Thiotepa was shown to impair fertility and interfere with spermatogenesis in male mice, and to impair ovarian function in female mice. It was teratogenic in mice and in rats, and foeto-lethal in rabbits. These effects were seen at doses lower than those used in humans.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Thiotepa is unstable in acid medium.<br />This medicinal product must not be mixed with other medicinal products except those<br />mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months

After reconstitution
Chemical and physical in-use stability after reconstitution has been demonstrated for 8 hours when stored at 2°C-8°C (36°-46°F)

After dilution
Chemical and physical in-use stability after dilution has been demonstrated for 24 hours when stored at 2°C -8°C (36°-46°F) and for 4 hours when stored at 25°C (77°F).

From a microbiological point of view, the product should be used immediately after dilution. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than the above-mentioned conditions when dilution has taken place in controlled and validated aseptic conditions.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C-8&deg;C). Do not freeze.<br /><u>After reconstitution and dilution</u><br />For storage conditions of the reconstituted and diluted medicinal product, see section 6.3.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Thiotepa for Injection USP 15mg/vial</strong>: Apeto is contained in a 3 mL USP Type-I clear lyo glass vial stoppered with 13 mm grey bromobutyl rubber closure and sealed with 13 mm aluminum flip-off seal with red color plastic polypropylene disc.<br /><strong>Thiotepa for Injection USP 100mg/vial:</strong> Apeto is contained in a 10 mL USP Type-I clear lyo glass vial stoppered with 20 mm igloo grey bromobutyl rubber closure and sealed with 20 mm<br />aluminum flip-off seal with orange-color plastic polypropylene disc.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Preparation of Apeto</u><br />Procedures for proper handling and disposal of anticancer medicinal products must be<br />considered. All transfer procedures require strict adherence to aseptic techniques, preferably<br />employing a vertical laminar flow safety hood.<br />As with other cytotoxic compounds, caution needs to be exercised in the handling and preparation of Apeto solutions to avoid accidental contact with skin or mucous membranes. Topical reactions associated with accidental exposure to thiotepa may occur. In fact, the use of gloves is recommended in preparing the solution for infusion. If the thiotepa solution accidentally contacts the skin, the skin must be immediately and thoroughly washed with soap and water. If thiotepa accidentally contacts mucous membranes, they must be flushed thoroughly with water.<br /><u>Reconstitution</u><br /><strong>Thiotepa for Injection USP 15mg/vial</strong><br />Thiotepa for Injection USP 15mg/vial must be reconstituted with 1.5 ml of sterile water for<br />injection USP.<br />Using a syringe fitted with a needle, aseptically withdraw 1.5 ml of sterile water for injection<br />USP.<br />Inject the content of the syringe into the vial through the rubber stopper.<br />Remove the syringe and the needle and mix manually by repeated inversions.<br />Only colorless solutions, without any particulate matter, must be used. Reconstituted solutions<br />may occasionally show opalescence; such solutions can still be administered.</p><p><u>Further dilution in the infusion bag</u><br />The reconstituted solution is hypotonic and must be further diluted prior to administration with<br />500 ml sodium chloride 9 mg/ml (0.9%) solution for injection (1000 ml if the dose is higher<br />then 500 mg) or with an appropriate volume of sodium chloride 9 mg/ml (0.9%) in order to<br />obtain a final Apeto concentration between 0.5 and 1 mg/ml.</p><p><strong>Thiotepa for Injection USP 100mg/vial</strong><br />Thiotepa for Injection USP 100mg/vial must be reconstituted with 10 ml of sterile water for<br />injection USP.<br />Using a syringe fitted with a needle, aseptically withdraw 10 ml of sterile water for injection<br />USP.<br />Inject the content of the syringe into the vial through the rubber stopper.<br />Remove the syringe and the needle and mix manually by repeated inversions.<br />Only colorless solutions, without any particulate matter, must be used. Reconstituted solutions<br />may occasionally show opalescence; such solutions can still be administered.<br /><u>Further dilution in the infusion bag</u><br />The reconstituted solution is hypotonic and must be further diluted prior to administration with<br />500 ml sodium chloride 9 mg/ml (0.9%) solution for injection (1000 ml if the dose is higher<br />than 500 mg) or with an appropriate volume of sodium chloride 9 mg/ml (0.9%) in order to<br />obtain a final Apeto concentration between 0.5 and 1 mg/ml.</p><p><u>Administration</u><br />Apeto should be inspected visually for particulate matter prior to administration. Solutions<br />containing a precipitate should be discarded.</p><p>Prior to and following each infusion, the indwelling catheter line should be flushed with<br />approximately 5 ml sodium chloride 9 mg/ml (0.9%) solution for injection.<br />The infusion solution must be administered to patients using an infusion set equipped with a<br />0.2 &mu;m in-line filter. Filtering does not alter solution potency.</p><p><u>Disposal</u><br />Apeto is for single use only.<br />Any unused product or waste material should be disposed of in accordance with local<br />requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Boston Oncology Arabia 
Sudair Industrial City, 
Sudair, Saudi Arabia 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                02/2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>